7.21
-2.42 (-25.10%)
| Previous Close | 9.62 |
| Open | 6.37 |
| Volume | 13,067,931 |
| Avg. Volume (3M) | 2,391,781 |
| Market Cap | 525,903,040 |
| Price / Sales | 2.39 |
| Price / Book | 1.07 |
| 52 Weeks Range | |
| Earnings Date | 1 May 2025 |
| Profit Margin | -75.51% |
| Operating Margin (TTM) | -98.31% |
| Diluted EPS (TTM) | -2.77 |
| Quarterly Revenue Growth (YOY) | 196.00% |
| Total Debt/Equity (MRQ) | 1.73% |
| Current Ratio (MRQ) | 4.64 |
| Operating Cash Flow (TTM) | -259.30 M |
| Levered Free Cash Flow (TTM) | -99.28 M |
| Return on Assets (TTM) | -13.05% |
| Return on Equity (TTM) | -32.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arvinas, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 7.62% |
| % Held by Institutions | 110.17% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 81.00 (HC Wainwright & Co., 1,024.22%) | Buy |
| Median | 26.00 (260.86%) | |
| Low | 12.00 (Goldman Sachs, 66.55%) | Hold |
| 12.00 (Morgan Stanley, 66.55%) | Hold | |
| 12.00 (Wedbush, 66.55%) | Hold | |
| Average | 30.08 (317.49%) | |
| Total | 9 Buy, 4 Hold | |
| Avg. Price @ Call | 11.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 17 Apr 2025 | 12.00 (66.55%) | Hold | 8.60 |
| Truist Securities | 09 Apr 2025 | 21.00 (191.46%) | Buy | 6.73 |
| HC Wainwright & Co. | 07 Apr 2025 | 81.00 (1,024.22%) | Buy | 6.37 |
| 14 Mar 2025 | 81.00 (1,024.22%) | Buy | 8.43 | |
| Guggenheim | 13 Mar 2025 | 32.00 (344.14%) | Buy | 8.55 |
| 12 Feb 2025 | 57.00 (691.12%) | Buy | 17.95 | |
| Morgan Stanley | 13 Mar 2025 | 12.00 (66.55%) | Hold | 8.55 |
| B of A Securities | 12 Mar 2025 | 28.00 (288.62%) | Buy | 9.03 |
| BMO Capital | 12 Mar 2025 | 20.00 (177.59%) | Buy | 9.03 |
| 12 Feb 2025 | 82.00 (1,038.10%) | Buy | 17.95 | |
| Wedbush | 12 Mar 2025 | 12.00 (66.55%) | Hold | 9.03 |
| Wells Fargo | 12 Mar 2025 | 26.00 (260.86%) | Buy | 9.03 |
| Citigroup | 07 Mar 2025 | 19.00 (163.71%) | Hold | 18.28 |
| Oppenheimer | 12 Feb 2025 | 45.00 (524.57%) | Buy | 17.95 |
| Stifel | 12 Feb 2025 | 51.00 (607.84%) | Buy | 17.95 |
| Barclays | 03 Feb 2025 | 32.00 (344.14%) | Buy | 17.10 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |